Pascal Furet

CCDC 2495077: Experimental Crystal Structure Determination

Markus Vögtle, Holger Sellner, Emilie Chapeau, Pascal Furet et autres

An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, …

Dissecting the Interaction Fingerprints and Binding Affinity of BYL719 Analogs Targeting PI3Kα

Sepehr Dehghani‐Ghahnaviyeh, Cihan Soylu, Pascal Furet, Camilo Velez‐Vega

Phosphatidylinositol-3-kinase Alpha (PI3Kα) is a lipid kinase which regulates signaling pathways involved in cell proliferation. Dysregulation of these pathways promotes several human cancers, pushing for the development of anticancer drugs to target PI3Kα. One such medicinal chemistry campaign at Novartis led to …

ch (code pays fourni par la source)

Identification of Brain-Penetrant ATP-Competitive mTOR Inhibitors for CNS Syndromes

Simone Bonazzi, Audrey J. Gray, Noel M. Thomsen, Jonathan D. Biag et autres

The allosteric inhibitor of the mechanistic target of rapamycin (mTOR) everolimus reduces seizures in tuberous sclerosis complex (TSC) patients through partial inhibition of mTOR functions. Due to its limited brain permeability, we sought to develop a catalytic mTOR inhibitor optimized for central …

us, ch (code pays fourni par la source)

Data from FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer

Andreas Jeffrey Weiss, Flavia Adler, Alexandra Buhles, Christelle Stamm et autres

Abstract Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver and it is the third leading cause of cancer-related deaths worldwide. Recently, aberrant signaling through the FGF19/FGFR4 axis has been implicated in HCC. Here, we describe the development of …

Data from Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

Christine M. Fritsch, Alan Huang, Christian Chatenay‐Rivauday, Christian Schnell et autres

Abstract Somatic PIK3CA mutations are frequently found in solid tumors, raising the hypothesis that selective inhibition of PI3Kα may have robust efficacy in PIK3CA-mutant cancers while sparing patients the side-effects associated with broader inhibition of the class I phosphoinositide 3-kinase (PI3K) family. …

Leveraging Advanced In Silico Techniques in Early Drug Discovery: A Study of Potent Small-Molecule YAP-TEAD PPI Disruptors

Ernest Awoonor‐Williams, Callum J. Dickson, Pascal Furet, Andrei A. Golosov et autres

Disruption of the YAP-TEAD protein–protein interaction is an attractive therapeutic strategy in oncology to suppress tumor progression and cancer metastasis. YAP binds to TEAD at a large flat binding interface (∼3500 Å 2 ) devoid of a well-defined druggable pocket, so it …

ch (code pays fourni par la source)

FGF401 characterizing data from FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer

Andreas Jeffrey Weiss, Flavia Adler, Alexandra Buhles, Christelle Stamm et autres

This file provides the full characterization of FGF401

Supplementary Materials and Methods from FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer

Andreas Jeffrey Weiss, Flavia Adler, Alexandra Buhles, Christelle Stamm et autres

Details on materials and methods

Supplementary Table S2 from FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer

Andreas Jeffrey Weiss, Flavia Adler, Alexandra Buhles, Christelle Stamm et autres

Pharmacologic profiling of FGF401 in cancer cell lines

Supplementary Table S4 from FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer

Andreas Jeffrey Weiss, Flavia Adler, Alexandra Buhles, Christelle Stamm et autres

Activity of FGF401 in PDXs

Supplementary Figure S1 from FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer

Andreas Jeffrey Weiss, Flavia Adler, Alexandra Buhles, Christelle Stamm et autres

FGF401 activity in cancer cell lines

Supplementary Figure S3 from FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer

Andreas Jeffrey Weiss, Flavia Adler, Alexandra Buhles, Christelle Stamm et autres

FGF401 versus sorafenib; FGF401 PD markers